COMP <GO>
RGEN vs LLY // PIOTROSKI F-SCORE QUALITY
Repligen Corporation (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: RGEN 3
— LLY 12
▲ PIOTROSKI F-SCORE QUALITY LEADER: LLY
LAST: $176.94 (-6.20%) • MKT CAP: $10.69B
piotroski-score
8/9
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
piotroski-score
9/9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RGEN VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RGEN | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 88.20% | 83.64% | +4.56 | RGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 2.30% | 32.36% | -30.06 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 36.4x | +58.58 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 0.88% | 2.30% | -1.42 | LLY | /fcf-yield <GO> |
| Operating Margin | 1.80% | 40.21% | -38.41 | LLY | /operating-margins <GO> |
| Net Profit Margin | 1.60% | 31.90% | -30.30 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | -3.30% | 45.51% | -48.81 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.31 | 9.29 | +0.02 | RGEN | /balance-sheet <GO> |
| Piotroski F-Score Quality ACTIVE | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.77% | +0.23 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 48.7 | 77.9 | -29.22 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.51 | +0.53 | RGEN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 140.0x | 26.3x | +113.75 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.69B | $1.33T | -$1.32T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RGEN REV | LLY REV | RGEN GROSS % | LLY GROSS % | RGEN FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | $93.9M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | $149.7M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | $113.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RGEN // BETA 1.04
LLY // BETA 0.51